Sanofi sees positive data in phase 3 tolebrutinib multiple sclerosis study

HJBC/iStock Editorial via Getty Images

• Sanofi (NASDAQ:SNY) said that data from the phase 3 HERCULES study showed that tolebrutinib given to multiple sclerosis patients slowed disability progression.
• The BTK inhibitor delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo.
• An